Dako’s HercepTest shows efficacy in trial

Dako has highlighted data from a recent clinical study which illustrates the effectiveness of its HercepTest diagnostic antibody.

The product was one of three HER2 antibodies to be tested by the University of Copenhagen's Faculty of Life Sciences in order to establish their effectiveness in identifying HER2-positive breast cancer patients.

It was shown that Dako's HercepTest and Leica Microsystems' Oracle reacted to HER2 without any cross-reaction to HER1, HER3 or HER4 occurring.

Hans Christian Pedersen, manager for immunohistochemistry PharmDx at Dako and a study co-author, said: "Using antibodies which cross-react with HER4 when testing for HER2 may potentially lead to an incorrect diagnosis and, in the worst case, to a patient receiving the wrong treatment."

Tests of this kind are important in determining which patients are likely to benefit from using drugs such as Herceptin.

Last month, Dako announced that it will be acting as a global distributor for a new test for measuring acute kidney injury from BioPorto Diagnostics.